title banner

OR in the News

OR in the News (selected articles)

Xing MW, Li CJ, Guo C, Wang BJ, Mu DL, Wang DX: Effect of intraoperative dexmedetomidine on long-term survival in older patients after major noncardiac surgery: 3-year follow-up of a randomized trial. J Clin Anesth 2023; 86: 111068

December 19, 2023

Study objective:
To assess the impact of intraoperative dexmedetomidine on long-term outcomes of older patients following major noncardiac surgery mainly for cancer.
Design: A long-term follow-up of patients enrolled in a randomized trial.
Setting: The initial trial was performed in a tertiary care hospital in Beijing, China.
Participants: Patients aged 60 years or older who were scheduled for major noncardiac surgery.
Intervention: Participants were randomized to receive either dexmedetomidine (a loading dose of 0.6 μg/kg over10 min, followed by a continuous infusion of 0.5 μg/kg/h until 1 h before end of surgery) or placebo during anesthesia.
Measurements: The primary endpoint was overall survival. Secondary endpoints included recurrence-free survival and event-free survival. Cox proportional hazard models were used to adjust for predefined confounding factors. Propensity score matching was employed for sensitive analysis.
Among 620 patients who were randomized in the initial trial, 619 were included in the long-term analysis (mean age 69 years, 40% female, 77% oncological surgery). The median follow-up duration was 42 months (interquartile range 41 to 45). Overall survival did not differ between the two groups: there were 49/309 (15.9%) deaths with dexmedetomidine versus 63/310 (20.3%) with placebo (adjusted hazard ratio [HR] 0.78, 95% CI 0.53–1.13, P = 0.187). Recurrence-free survival was improved with dexmedetomidine (68/309 [22.0%] events with dexmedetomidine versus 98/310 [31.6%] with placebo; adjusted HR 0.67, 95% CI 0.49–0.92, P = 0.012). Event-free survival was also improved with dexmedetomidine (120/309 [38.8%] events with dexme- detomidine versus 145/310 [46.8%] with placebo; adjusted HR 0.78, 95% CI 0.61–1.00, P = 0.047). Results were similar after propensity-score matching and in the subgroup of cancer patients
In older patients having major noncardiac surgery mainly for cancer, intraoperative dexmedeto- midine did not improve overall survival but was associated with improved recurrence-free and event-free survivals.